STAB (Statera BioPharma) Other Long Term Assets: $-0.00 Mil (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Statera BioPharma Other Long Term Assets?

Statera BioPharma STAB Other Long Term Assets is $-0.00 Mil as of Sep. 2022.

Statera BioPharma's other long-term assets for the quarter that ended in Sep. 2022 was $-0.00 Mil.

Statera BioPharma's quarterly other long-term assets declined from Mar. 2022 ($-0.00 Mil) to Jun. 2022 ($-0.00 Mil) but then increased from Jun. 2022 ($-0.00 Mil) to Sep. 2022 ($-0.00 Mil).

Statera BioPharma's annual other long-term assets declined from Dec. 2019 ($0.00 Mil) to Dec. 2020 ($-0.00 Mil) but then increased from Dec. 2020 ($-0.00 Mil) to Dec. 2021 ($5.00 Mil).

Statera BioPharma Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Other Long Term Assets Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Other Long Term Assets
0.00 -0.00 5.00

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 5.19 5.00 -0.00 -0.00 -0.00

Statera BioPharma Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $-0.00 Mil mean?
Statera BioPharma (STAB) has a Other Long Term Assets of $-0.00 Mil as of Sep. 2022. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's Other Long Term Assets too high?
Statera BioPharma's current Other Long Term Assets is $-0.00 Mil.
How does Statera BioPharma's Other Long Term Assets compare to NRBO and PALI?
Statera BioPharma's Other Long Term Assets of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current Other Long Term Assets is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (STAB) has a current Other Long Term Assets of $-0.00 Mil. The current Other Long Term Assets is $-0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Statera BioPharma (STAB), the current Other Long Term Assets is $-0.00 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.